循環器ジャーナル67巻4号

2019年10月発行

特集 冠動脈疾患のリスク管理のフロントライン Ⅰ．冠動脈疾患イベントリスクをどう評価する？

血液バイオマーカーでどう評価する？

著者： 井上晃男¹

所属機関： ¹獨協医科大学内科学（心臓・血管/循環器）

ページ範囲：P.572 - P.578

Point
・これまで様々な血管不全バイオマーカーが研究されてきた．なかでもCRPとcTnは高感度測定法が開発され，その有用性が高まった．
・CRPは血管不全の各段階で，病態把握や予後予測に有力な炎症マーカーであり，多くの大規模臨床試験で用いられている．実臨床の場での診療に応用するためにはCRPを含むいくつかのマーカーの組み合わせによるmultiple biomarker strategyを目指すべきと考える．
・心筋傷害マーカーであるcTnは血管不全の終末像である急性心筋梗塞の診断に有用なマーカーであり，今後はcTnを基にした急性心筋梗塞の早期診断が本邦でも益々普及することが予想されるが，false positiveには警戒が必要である．

参考文献

1) Koenig W, Khuseyinova N:Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 27:15-26, 2007

2) Inoue T, Node K:Vascular failure:a new clinical entity for vascular disease. J Hypertens 24:2121-2130, 2006

3) Kinlay S, Selwyn AP, Libby P, et al:Inflammation, the endothelium, and the acute coronary syndrome. J Cardiovasc Pharmacol 32:S62-S66, 1998

4) Szmitko PE, Wang C, Weisel RD, et al:New markers of inflammation and endothelial cell activation:part I. Circulation 108:1917-1923, 2003

5) Morrow DA, de Lemos JA, Sabatine MS, et al:Clinical relevance of C-reactive protein during follow-up of patients with acute myocardial infarction. Circulation 114:281-288, 2006

6) Braunwald E, Antman EM, Beasley JW, et al:ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines（Committee on the Management of Patients With Unstable Angina）. J Am Coll Cardiol 36:970-1062, 2000

7) Inoue T, Kato T, Uchida T, et al:Local release of C-reactive protein from the vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 46:239-245, 2005

8) Gaspardone, Tomai F, Versaci F, et al:Coronary artery stent placement in patients with variant angina refractory to medical treatment. Am J Cardiol 84:96-98, 1999

9) Kinlay S, Schwartz GG, Olsson AG, et al:High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108:1560-1566, 2003

10) Ridker PM, Danielson E, Fonseca FA, et al:Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207, 2008

11) Taguchi I, Iimuro S, Iwata H, et al:High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease（REAL-CAD）:a randomized superiority trial. Circulation 137:1997-2009, 2018

12) Ridker PM, Everett BM, Thuren T, et al:Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377:1119-1131, 2017

13) Ridker PM, MacFadyen JG, Everett BM, et al:Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab:a secondary analysis from the CANTOS randomised controlled trial. Lancet 391:319-328, 2018

14) Ridker PM, MacFadyen JG, Thuren T, et al:Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis:exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390:1833-1842, 2017

15) Kenny WJL, John SH, Keith R, et al:Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. CMAJ 174:461-466, 2006

16) Keller T, Zeller T, Peetz D, et al:Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868-877, 2009

17) Antman EM, Sacks DB, Rifai N, et al:Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes:a Thrombolysis in Myocardial Infarction（TIMI）11A substudy. J Am Coll Cardiol 31:326-330, 1998

18) Perna ER, Macin SM, Canella JP, et al:Ongoing myocardial injury in stable severe heart failure. Value of cardiac troponin T monitoring for high-risk patient identification. Circulation 110:2376-2382, 2004

19) Horwich TB, Patel J, MacLellan WR, et al:Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality tastes in advanced heart failure. Circulation 108:833-838, 2003

20) Thygesen K, Alpert JS, Jaffe AS, et al:Third universal definition of myocardial infarction. Circulation 126:2020-2035, 2012

21) Ishihara M, Nakao K, Ozaki Y, et al:Long-term outcomes of non-ST-elevation myocardial infarction without creatine kinase elevation:the J-MINUET study. Circ J 81:958-965, 2017